L'intérêt à découvert pour VanEck Digital Transformation ETF donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de VanEck Digital Transformation ETF. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

VanEck Digital Transformation ETF (NASDAQ:DAPP), Rapport sur les intérêts à découvert

VanEck Digital Transformation ETF

Technology

Financial Services

Communication Services

Other

The Fund normally invests at least 80 percent of its total assets in securities of Digital Transformation Companies. The Digital Transformation Index is a global index that tracks the performance of Digital Transformation Companies. Digital Transformation Companies are companies (i) that operate digital asset exchanges, operate payment gateways (i.e., a merchant service that authorizes direct payments processing for businesses), engage in or assist with the digital asset mining operations, provide software services, equipment and technology or services to digital asset operations, operate digital asset infrastructure businesses, or facilitate commerce with the use of digital assets (these items are collectively referred to herein as digital asset projects) and/or (ii) that own a material amount of digital assets or otherwise generate revenues related to digital asset projects.

Block Inc

Coinbase Global Inc

Mara Holdings Inc

Applied Digital Corp

Hut 8 Corp

Northern Data Ag

Terawulf Inc

Cleanspark Inc

Microstrategy Inc

Iris Energy Ltd

Bitdeer Technologies Group

Core Scientific Inc

Riot Platforms, Inc.

Galaxy Digital Inc

Metaplanet Inc

Defi Technologies, Inc.

LiquidApps

Mizuho analyst Dan Dolev maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Outperform and lowers the price target from $365 to $348.

News

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Accenture, Lowers Price Target to $348

<a href="https://www.globenewswire.com/Tracker?data=74jPtEAje6rPMHkOb9otDIJUstt9a7iyXFpLIa1oJP0-tiNzNXOZzIjjQiUed3t-_RN4aiTQvz1Td1kFZ-4tOg==">Gogo</a> (NASDAQ:<a href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) has confirmed its Gogo C1 line replaceable unit (LRU) has received Supplemental Type Certification (STC) for 42 aircraft models through an Approved Model List (AML) granted by the Federal Aviation Administration (FAA). The confirmation covers 70% of North American Gogo legacy air-to-ground (ATG) customer aircraft and, once equipped, will ensure continued compatibility with and connectivity to Gogo's forthcoming LTE network upgrade.
Metrea Aerospace Design (MASD) collaborated with Gogo to generate the AML STC, which covers aircraft including Cessna Citation, Gulfstream, Bombardier Challenger and Learjet, Dassault Falcon, Embraer, and Hawker family models. Equipping the Gogo C1 will enable current customers operating with legacy ATG 1000, 2000, 4000 or 5000 systems to seamlessly transition to the upgraded Gogo Biz North American 850MHz Licensed LTE network when it comes online in May 2026 to ensure uninterrupted service. The Gogo C1 LRU also provides a practical bridging capability for customers planning to switch up to Gogo AVANCE products, which enables optimized inflight productivity through internet, voice, streaming, popular pilot applications, and more.

GOGO

Gogo Confirms Supplemental Type Certification For Gogo C1 Line Replaceable Unit For 42 Aircraft Models Through Approved Model List Granted By FAA

Nektar Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock is surging on Tuesday, with a session volume of 4.7 million compared to an average volume 239.7K as per data <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">from Benzinga Pro</a>.
The company released statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46070929/rezolve-ad-phase-2b-study-of-rezpegaldesleukin-meets-primary-and-key-secondary-endpoints-in-patien" rel="noreferrer noopener">investigational rezpegaldesleukin</a>.
The global Phase 2b study is being conducted in 393 patients with moderate-to-severe <a href="https://www.benzinga.com/general/health-care">atopic dermatitis</a>. Patients in the study received three under-the-skin shots of rezpegaldesleukin.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupix" target="_blank" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
The trial met its primary endpoint of the mean improvement in Eczema Area and Severity Score (EASI) from baseline at week 16 for all three dose arms of rezpegaldesleukin versus placebo.
All three dose arms also achieved statistical significance at week 16 for the key secondary endpoints of EASI-75 (percent of patients who achieve ≥75% reduction in EASI from baseline), EASI-50 (percent of patients who achieve ≥50% reduction in EASI from baseline) and BSA (mean percent improvement in Body Surface Area score from baseline).
After 16 weeks, patients had a 53% to 61% improvement in symptoms. This was compared to a 31% improvement for the placebo group.
The q2w arms of rezpegaldesleukin (high and middle doses) achieved statistical significance at week 16 for the key secondary endpoints of vIGA-AD 0/1 (percent of patients achieving a score of 0 or 1 on the validated Investigator&#8217;s Global Assessment for Atopic Dermatitis with ≥ 2-point reduction&nbsp;from baseline) and Itch NRS (percent of patients with baseline ≥ 4 who experienced a ≥&nbsp;4-point reduction&nbsp;in the Itch Numerical Rating Score from baseline).
In addition, at week 16, the high dose of 24 µg/kg q2w achieved statistical significance on EASI-90 (percent of patients who achieve ≥ 90% reduction in EASI from baseline).
Across all three dose arms, translational blood biomarker data demonstrate robust on-target and dose-dependent pharmacological activity.
The safety profile for the 16-week induction period for rezpegaldesleukin was consistent with previously reported results.
In the pooled rezpegaldesleukin arms, TEAEs, excluding ISRs, were reported in 60.3% of patients and in 57.5% of placebo-treated patients.
There was no increased risk of conjunctivitis, oral ulcers, or infections, including oral herpes, in the rezpegaldesleukin arms.
Nektar plans to submit these REZOLVE-AD 16-week induction results for presentation at a medical conference later in 2025.
Price Action: NKTR stock is trading higher by 108.6% to $19.90 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46071029/mark-zuckerbergs-ai-dreams-hit-whatsapp-speed-bump-as-openai-perplexity-challenge-meta-on-its-own-turf-report" target="_blank" rel="noreferrer noopener">Mark Zuckerberg&#8217;s AI Dreams Hit WhatsApp Speed Bump As OpenAI, Perplexity Challenge Meta On Its Own Turf: Report</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

NKTR

Nektar Therapeutics Shares Double On Promising Eczema Drug Data

GNPX

Genprex Collaborators Present Preclinical Research On Diabetes Gene Therapy At 2025 ADA Scientific Sessions; Latest Research Shows Improved Glucose Homeostasis By Reprogramming Alpha Cells

&nbsp;Today, WF Holding Ltd (stock code: WFF) officially announced its entry into the cryptocurrency sector and appointed Bull Coin Asset Management Limited as its industry consultant. The collaboration aims to assist with market research, technology assessment, and compliance strategy development. This move marks a significant step for WF Holding Ltd in blockchain technology innovation and the construction of a digital financial ecosystem. Moving forward, the company plans to leverage technological innovation, compliance operations, and ecosystem collaboration to drive the integration of digital assets with the real economy, creating long-term value for both shareholders and customers.
In light of the rapid growth of the cryptocurrency market and the widespread application of blockchain technology, WF Holding Ltd has decided to actively explore this emerging field to enhance the company's technological competitiveness and future growth potential. Bull Coin Asset Management Limited will provide the company with comprehensive support for subsequent business expansion efforts by utilizing its expertise in digital asset research and global resources
The company stated that "Cryptocurrencies and blockchain technology are reshaping global financial and business infrastructure. It is a necessary step for technological innovation and a strategic measure to respond to customer and market demand."

WF Holding Enters Cryptocurrency Sector, Appoints Bull Coin Asset Management As Consultant; Collaboration Aims To Assist With Market Research, Technology Assessment, And Compliance Strategy Development

JP Morgan analyst DS Kim upgrades New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Neutral to Overweight and raises the price target from $48 to $62.

Upgrades

New Oriental Education & Technology Group

JP Morgan Upgrades New Oriental Education to Overweight, Raises Price Target to $62

Morgan Stanley analyst Megan Alexander maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Underweight and lowers the price target from $53 to $51.

Morgan Stanley Maintains Underweight on General Mills, Lowers Price Target to $51

Ford Motor Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) is determined to move forward with the construction of its $3 billion&nbsp;battery plant in Michigan, even&nbsp;if the project loses its eligibility for federal tax incentives.
What Happened:&nbsp;Ford&#8217;s decision to continue with the project comes amid potential policy changes by the U.S. government that could render the plant ineligible for federal tax credits, <a href="https://www.nytimes.com/2025/06/23/business/ford-battery-factory-electric-vehicles.html">reported</a>&nbsp;The New York Times&nbsp;on Monday.&nbsp;The plant, located in Marshall, Michigan, is expected to utilize battery and manufacturing technology licensed from the Chinese company&nbsp;Contemporary Amperex Technology Ltd.&nbsp;(CATL).
The Inflation Reduction Act, a key energy and climate change legislation passed under the administration of former President Joe Biden, was anticipated to provide federal tax credits to offset a portion of the plant&#8217;s costs. However, current Republican efforts in Congress may result in the exclusion of battery plants using Chinese technology or materials from federal support. 
Despite these potential changes, Ford is committed to the project.&nbsp;Lisa Drake, Ford&#8217;s&nbsp;vice president for technology platform&nbsp;programs and E.V. systems, stated, &#8220;We&nbsp;don't want to back off&nbsp;on this facility. When&nbsp;we invest, we stick behind&nbsp;our investments. Ford is a&nbsp;company that will weather the&nbsp;storm until we get there.&#8221;
The plant, scheduled to commence production next year, is projected to create 1,700 jobs and produce batteries using lithium, iron, and phosphate. 
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/large-cap/25/06/46044073/small-investment-bank-tied-to-trumps-sons-facilitated-120-million-trading-windfall" target="_blank" rel="noreferrer noopener">Small Investment Bank Tied to Trump's Sons Facilitated $120 Million Trading Windfall &#8211; Benzinga</a>
Why It Matters: The potential loss of tax incentives for Ford&#8217;s battery plant comes amid President Donald Trump&#8216;s crackdown on all-electric mobility in the country. 
Senate Republicans have proposed a bill to end the $7500 EV credit<a href="https://www.benzinga.com/markets/tech/25/06/45965638/amid-trumps-anti-ev-push-senate-republicans-propose-tax-bill-to-axe-7500-ev-credit"> currently available </a>on EV purchases within 180 days after the proposal is signed into law. 
Earlier in February, automakers like General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford had appealed to lawmakers to gradually phase out electric-vehicle (EV) tax credits over several years, rather than <a href="https://www.benzinga.com/markets/25/02/43648415/tesla-rivals-call-for-gradual-elimination-of-ev-tax-credits-many-of-those-jobs-will-be-at-risk">abruptly ending</a> them.
On a year-to-date basis, shares of Ford surged 11.4% as per<a href="https://www.benzinga.com/pro/"> Benzinga Pro</a>.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/46068633/ford-recalls-aviator-suvs-as-adhesive-issue-adds-to-automakers-mounting-recall-woes">Ford Recalls Aviator SUVs As Adhesive Issue Adds To Automaker&#8217;s Mounting Recall Woes</a> </li>
<li>Image via Shutterstock</li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Ford To Proceed With $3 Billion Battery Plant Despite Potential Tax Incentive Loss Under Trump's Budget Plan: 'We Stick Behind Our Investments'

Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) is looking for Q3 Adj EPS of $1.30 vs $1.32 analyst estimate..

Guidance

Carnival Sees Q3 Adj EPS $1.30 vs $1.32 Est

WF Holding Plans To Make Investments In China To Expand Business Scope And Promote Bilateral Economic Cooperation And Technological Exchanges

Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) raises FY2025 Adj EPS guidance from $1.83 to $1.97 vs $1.89 analyst estimate..

Carnival Raises FY2025 Adj EPS Guidance from $1.83 to $1.97 vs $1.89 Est

Stephens &amp; Co. analyst Sudan Loganathan upgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Equal-Weight to Overweight and raises the price target from $29 to $60.

EXEL

Stephens & Co. Upgrades Exelixis to Overweight, Raises Price Target to $60

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Live On CNBC, Visa CEO Ryan McInerney Says "We've Been Embracing Stablecoins"

-AI Audience + AI Creative AI agent solution – integrates language models and generative technologies for marketing process automation by utilizing five intelligent models &nbsp;
-Proprietary AI-powered content management system supports media brands in improving editorial efficiency and content exposure &nbsp;
-AI-based display ad optimization drives revenue growth in display ad segment of Media &amp; Branded Content business unit &nbsp;
-AI-driven cost reduction initiatives drove 5% reduction in group-level human capital intensity in May vs. same month last year
NEW YORK and TOKYO, June 24, 2025 /PRNewswire/ -- TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) (the "Company"), a Tokyo-based next-generation digital media and data group in Asia, today announced a collection of new AI-based initiatives focused on boosting productivity at the Company, including the launch of both its AI Agent product "AI Audience + AI Creative", AI-driven display ad revenue optimization and AI-driven cost reduction initiatives that have lowered group-level human capital intensity by 5%.

TNMG

TNL Mediagene Launches AI Agent Solution "AI Audience + AI Creative", Ad Optimization, And Cost-Cutting Initiatives, Reducing Human Capital Intensity By 5% In May Vs. Same Month Last Year

Carnival Corporation Sees Q3 Net Yields Up Approximately 3.5% Compared To 2024 Levels, Which Were Up Almost 9%

Barclays analyst Luke Sergott initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Equal-Weight rating and announces Price Target of $245.

Initiation

Barclays Initiates Coverage On West Pharmaceutical Servs with Equal-Weight Rating, Announces Price Target of $245

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and maintains $715 price target.

Reiteration

ARGX

Wedbush Reiterates Outperform on argenx, Maintains $715 Price Target

Morgan Stanley analyst Toni Kaplan maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Underweight and raises the price target from $390 to $393.

Morgan Stanley Maintains Underweight on FactSet Research Systems, Raises Price Target to $393

For the full year 2025, the company expects:
<ul>
<li>Net yields (in constant currency) approximately 5.0 percent higher than strong 2024 levels, which were up 11 percent and 0.3 percentage points better than March guidance.</li>
<li>Adjusted cruise costs excluding fuel per ALBD (in constant currency) up approximately 3.6 percent compared to 2024, better than March guidance.</li>
<li>Adjusted net income up over 40 percent compared to 2024 and better than March guidance by $200 million.</li>
<li>Adjusted EBITDA of approximately $6.9 billion, up over 10 percent compared to 2024 and better than March guidance.</li>
</ul>

Carnival Corporation Sees FY25 Net Yields Approximately 5% Higher Than 2024 Levels, Which Were Up 11%

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone
- Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP
CHICAGO and FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today highlighted results from a pre-specified subgroup analysis of its Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC).
Patients treated for at least one complete cycle (4 weeks) of therapy achieved a median overall survival (mOS) of 12.5 months in the elragusib/GnP arm, compared to 8.5 months in the control arm. The analysis showed a 43% reduction in the risk of death relative to control, highlighting the significant potential impact of early disease control by elraglusib. Improved outcomes were reported in the combination versus control arms, respectively: disease control rate (DCR): 53.4% vs 44.8%, overall response rate (ORR): 37.9% vs 29.3%, and median progression-free survival (PFS): 6.9 vs 5.6 months.

ACTU

Actuate Therapeutics Highlights Results From Pre-Specified Subgroup Analysis Of Phase 2 Trial Of Elraglusib In Combination With GnP In First-Line Metastatic Pancreatic Adenocarcinoma

Comments

VanEck Digital Transformation ETF

Intérêt court

VanEck Digital Transformation ETF (NASDAQ:DAPP), Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL